{"id":3650299,"date":"2024-06-03T08:00:00","date_gmt":"2024-06-03T12:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\/"},"modified":"2025-12-31T12:58:07","modified_gmt":"2025-12-31T17:58:07","slug":"moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\/","title":{"rendered":"Moderna &#038; Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival &#038; Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III\/IV Melanoma Following Complete Resection"},"content":{"rendered":"<p><!-- \n\n<p style=\"text-align: center\">\n  <strong>\n    Moderna & Merck Announce Three-Year Data for mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival Versus Keytruda in Patients With High-Risk Stage III\/IV Melanoma Following Complete Resection\n  <\/strong>\n<\/p>\n\n --><\/p>\n<p style=\"text-align: center\">\n    <strong><br \/>\n        At a median planned follow-up of the Phase 2b study at 34.9 months,<br \/>\n        mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence<br \/>\n        or death by 49% and the risk of distant metastasis or death by 62% compared<br \/>\n        to KEYTRUDA alone in these patients<br \/>\n    <\/strong>\n<\/p>\n<p style=\"text-align: center\">\n    <strong><br \/>\n        The 2.5-year recurrence-free survival rate of mRNA-4157 (V940) in<br \/>\n        combination with KEYTRUDA was 74.8% as compared to 55.6% for KEYTRUDA alone,<br \/>\n        with the benefit observed across exploratory subgroups<br \/>\n    <\/strong>\n<\/p>\n<p style=\"text-align: center\">\n    <strong><br \/>\n        The companies have initiated Phase 3 studies in patients with high-risk<br \/>\n        melanoma and non-small cell lung cancer, in addition to Phase 2 studies in<br \/>\n        patients with renal cell carcinoma and urothelial carcinoma and a Phase 2\/3<br \/>\n        study for cutaneous squamous cell carcinoma<br \/>\n    <\/strong>\n<\/p>\n<p>\n    CAMBRIDGE, Mass. and RAHWAY, N.J., June 3, 2024 \u2013 Moderna, Inc. (NASDAQ: MRNA)<br \/>\n    and Merck (NYSE: MRK), known as MSD outside of the United States and Canada,<br \/>\n    today announced the first presentation of results from a planned analysis from<br \/>\n    the Phase 2b randomized KEYNOTE-942\/mRNA-4157-P201 study, a clinical trial<br \/>\n    evaluating mRNA-4157 (V940), an investigational individualized neoantigen<br \/>\n    therapy (INT), in combination with KEYTRUDA, Merck&#8217;s anti-PD-1 therapy, in<br \/>\n    patients with resected high-risk melanoma (stage III\/IV) following complete<br \/>\n    resection (n=157). With a median follow-up of approximately three years (34.9<br \/>\n    months), adjuvant treatment with mRNA-4157 (V940) in combination with KEYTRUDA<br \/>\n    continued to demonstrate a clinically meaningful and durable improvement in<br \/>\n    recurrence-free survival (RFS), the primary endpoint of the study, reducing<br \/>\n    the risk of recurrence or death by 49% (HR [95% CI], 0.510 [0.288\u20130.906];<br \/>\n    two-sided nominal p-value 0.019) compared with KEYTRUDA alone. mRNA-4157<br \/>\n    (V940) in combination with KEYTRUDA also continued to demonstrate a meaningful<br \/>\n    improvement in distant metastasis-free survival (DMFS), a key secondary<br \/>\n    endpoint of the study, compared with KEYTRUDA alone, reducing the risk of<br \/>\n    developing distant metastasis or death by 62% (HR [95% CI], 0.384<br \/>\n    [0.172\u20130.858], two-sided nominal p-value 0.015).\n<\/p>\n<p>\n    These data are being presented today during a rapid oral abstract session at<br \/>\n    the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (abstract<br \/>\n    #LBA9512). With an additional year of planned follow-up, these data build on<br \/>\n    the earlier analysis of the <a href=\"https:\/\/www.merck.com\/news\/moderna-and-merck-announce-mrna-4157-v940-an-investigational-individualized-neoantigen-therapy-in-combination-with-keytruda-pembrolizumab-demonstrated-superior-recurrence-free-survival-in\/\">primary<\/a><br \/>\n    and key<br \/>\n    <a href=\"https:\/\/www.merck.com\/news\/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free\/\">secondary<br \/>\n        endpoints<\/a><br \/>\n    of the study, presented in 2023. The 2.5-year RFS rate of mRNA-4157 (V940) in<br \/>\n    combination with KEYTRUDA was 74.8%, as compared to 55.6% for KEYTRUDA alone,<br \/>\n    with the benefit observed across exploratory subgroups.\n<\/p>\n<p>\n    \u201cWe are encouraged by the latest results from the KEYNOTE-942\/mRNA-4157-P201<br \/>\n    study. These data highlight the sustained benefit in RFS and DMFS of mRNA-4157<br \/>\n    (V940) as adjuvant treatment in combination with KEYTRUDA in people with<br \/>\n    resected high-risk melanoma. Importantly, this benefit was observed across<br \/>\n    various patient exploratory subgroups, reflecting the potential of mRNA-4157<br \/>\n    (V940) for a broad range of these patients,\u201d said Kyle Holen, M.D., Moderna&#8217;s<br \/>\n    Senior Vice President and Head of Development, Therapeutics and Oncology.<br \/>\n    \u201cThese findings reinforce our commitment to advancing this innovative<br \/>\n    treatment in collaboration with Merck, and we are dedicated to harnessing mRNA<br \/>\n    technology to potentially transform cancer therapy and improve patient<br \/>\n    outcomes.\u201d\n<\/p>\n<p>\n    \u201cThe sustained improvements in recurrence-free survival and distant<br \/>\n    metastasis-free survival observed at approximately three years in the<br \/>\n    KEYNOTE-942\/mRNA-4157-P201 study provide further support of the potential of<br \/>\n    mRNA-4157 (V940) in combination with KEYTRUDA to help patients with resected<br \/>\n    high-risk melanoma,\u201d said Dr. Marjorie Green, senior vice president and head<br \/>\n    of oncology, global clinical development, Merck Research Laboratories. \u201cWe<br \/>\n    look forward to building on our legacy of turning breakthrough science into<br \/>\n    medicines that may have a meaningful impact on patients\u2019 lives as we continue<br \/>\n    advancing our broad clinical development program evaluating this novel<br \/>\n    approach with Moderna.\u201d\n<\/p>\n<p>\n    <strong>Additional efficacy and subgroup data<\/strong>\n<\/p>\n<p>\n    Data from an exploratory subgroup analysis of the Phase 2b<br \/>\n    KEYNOTE-942\/mRNA-4157-P201 study in patients with resected high-risk melanoma<br \/>\n    (stage III\/IV) following complete resection showed that improvement in RFS was<br \/>\n    observed with mRNA-4157 (V940) in combination with KEYTRUDA compared to<br \/>\n    KEYTRUDA alone regardless of tumor mutational burden (TMB) or programmed<br \/>\n    death-ligand 1 (PD-L1) status.\n<\/p>\n<p>\n    The RFS benefit of mRNA-4157 (V940) in combination with KEYTRUDA compared to<br \/>\n    KEYTRUDA alone was maintained across both TMB high (HR [95% CI], 0.564<br \/>\n    [0.253\u20131.258]), TMB non-high (0.571 [0.245\u20131.331]), PD-L1 positive (0.471<br \/>\n    [0.226\u20130.979]), PD-L1 negative (0.147 [0.034\u20130.630]), and circulating tumor<br \/>\n    DNA (ctDNA) negative (0.207 [0.091\u20130.470]) subpopulations. ctDNA positive HR<br \/>\n    was not estimable due to the small sample size. There were no significant<br \/>\n    associations between individual human leukocyte antigen (HLA) alleles and RFS<br \/>\n    observed for mRNA-4157 (V940) in combination with KEYTRUDA.\n<\/p>\n<p>\n    The exploratory endpoint of overall survival (OS) favored mRNA-4157 (V940) in<br \/>\n    combination with KEYTRUDA compared to KEYTRUDA alone, with a 2.5-year OS rate<br \/>\n    of 96.0% vs. 90.2%, respectively (HR [95% CI], 0.425 [0.114\u20131.584]).\n<\/p>\n<p>\n    The safety profile with mRNA-4157 (V940) in combination with KEYTRUDA in<br \/>\n    KEYNOTE-942\/mRNA-4157-P201 remains consistent with the primary analysis. The<br \/>\n    most common adverse events attributed to mRNA-4157 (V940) in combination with<br \/>\n    KEYTRUDA were fatigue (60.6%), injection site pain (56.7%), and chills<br \/>\n    (49.0%). The majority of the adverse events attributed to mRNA-4157 (V940)<br \/>\n    were Grade 1-2, with fatigue being the most common Grade 3 event and no Grade<br \/>\n    4-5 events. Immune-related adverse events occurred in 37.5% of patients<br \/>\n    receiving the combination and 36% receiving KEYTRUDA alone.\n<\/p>\n<p>\n    <strong>Ongoing clinical development programs<\/strong>\n<\/p>\n<p>\n    Merck and Moderna have initiated Phase 3 randomized clinical trials evaluating<br \/>\n    mRNA-4157 (V940) in combination with KEYTRUDA as an adjuvant treatment in<br \/>\n    patients with resected high-risk (Stage IIB-IV) melanoma (INTerpath-001,<br \/>\n    <a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05933577\">NCT05933577<\/a>) and non-small cell lung cancer<br \/>\n    (INTerpath-002,<br \/>\n    <a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT06077760?intr=mRNA-4157&amp;rank=3\">NCT06077760<\/a>). Both trials<br \/>\n    are actively enrolling.\n<\/p>\n<p>\n    In 2024, Merck and Moderna also initiated a two-part Phase 2\/3 randomized<br \/>\n    clinical trial evaluating mRNA-4157 (V940) in combination with KEYTRUDA as<br \/>\n    neoadjuvant and adjuvant treatment in patients with resectable locally<br \/>\n    advanced Stage II-IV (M0) cutaneous squamous cell carcinoma (INTerpath-007,<br \/>\n    <a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06295809\">NCT06295809<\/a>), a Phase 2 randomized clinical<br \/>\n    trial evaluating mRNA-4157 (V940) in<br \/>\n    combination with KEYTRUDA as adjuvant treatment in patients with<br \/>\n    intermediate-high-risk, high-risk, or M1 no evidence of disease renal cell<br \/>\n    carcinoma (INTerpath-004,<br \/>\n    <a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT06307431?term=NCT06307431&amp;rank=1\">NCT06307431<\/a>), and a Phase<br \/>\n    2 randomized clinical trial evaluating mRNA-4157 (V940) in<br \/>\n    combination with KEYTRUDA as adjuvant treatment in patients with high-risk<br \/>\n    muscle-invasive urothelial carcinoma post-radical resection (INTerpath-005,<br \/>\n    <a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT06305767?term=V940-005&amp;rank=1\">NCT06305767<\/a>).\n<\/p>\n<p>\n    <strong>About mRNA-4157 (V940)<\/strong>\n<\/p>\n<p>\n    mRNA-4157 (V940) is a novel investigational messenger RNA (mRNA)-based<br \/>\n    individualized neoantigen therapy (INT) consisting of a synthetic mRNA coding<br \/>\n    for up to 34 neoantigens that is designed and produced based on the unique<br \/>\n    mutational signature of the DNA sequence of the patient\u2019s tumor. Upon<br \/>\n    administration into the body, the algorithmically derived and RNA-encoded<br \/>\n    neoantigen sequences are endogenously translated and undergo natural cellular<br \/>\n    antigen processing and presentation, a key step in adaptive immunity.\n<\/p>\n<p>\n    Individualized neoantigen therapies are designed to train and activate an<br \/>\n    antitumor immune response by generating specific T-cell responses based on the<br \/>\n    unique mutational signature of a patient\u2019s tumor. KEYTRUDA is an immunotherapy<br \/>\n    that works by increasing the ability of the body\u2019s immune system to help<br \/>\n    detect and fight tumor cells. As previously<br \/>\n    <a href=\"https:\/\/www.merck.com\/news\/moderna-and-merck-announce-mrna-4157-v940-an-investigational-individualized-neoantigen-therapy-in-combination-with-keytruda-pembrolizumab-demonstrated-superior-recurrence-free-survival-in\/\">announced<\/a><br \/>\n    from the Phase 2b KEYNOTE-942\/mRNA-4157-P201 trial evaluating patients with<br \/>\n    high-risk stage III\/IV melanoma, combining mRNA-4157 (V940) with KEYTRUDA may<br \/>\n    provide a meaningful benefit over KEYTRUDA alone.\n<\/p>\n<p>\n    <strong><br \/>\n        About KEYNOTE-942\/mRNA-4157-P201 (<a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT03897881\">NCT03897881<\/a>)<br \/>\n    <\/strong>\n<\/p>\n<p>\n    KEYNOTE-942 is an ongoing randomized, open-label Phase 2b trial that enrolled<br \/>\n    157 patients with high-risk stage III\/IV melanoma. Following complete surgical<br \/>\n    resection, patients were assigned 2:1 (stratified by stage) to receive<br \/>\n    mRNA-4157 (V940) (1 mg every three weeks for nine doses) and KEYTRUDA (200 mg<br \/>\n    every three weeks up to 18 cycles [for approximately one year]) versus<br \/>\n    KEYTRUDA alone for approximately one year until disease recurrence or<br \/>\n    unacceptable toxicity. The primary endpoint is RFS, defined as the time from<br \/>\n    first dose of KEYTRUDA until the date of first recurrence (local, regional, or<br \/>\n    distant metastasis), a new primary melanoma, or death from any cause in the<br \/>\n    intention-to-treat population. Secondary endpoints include distant<br \/>\n    metastasis-free survival and safety, and exploratory endpoints include<br \/>\n    distribution of TMB expression in baseline tumor samples across study arms and<br \/>\n    their association with the primary RFS endpoint. The KEYNOTE-942 trial is<br \/>\n    ongoing to collect additional translational data and an additional 100<br \/>\n    patients are currently being enrolled.\n<\/p>\n<p>\n    Key eligibility criteria for the trial included: patients with resectable<br \/>\n    cutaneous melanoma metastatic to a lymph node and at high risk of recurrence,<br \/>\n    patients with complete resection within 13 weeks prior to the first dose of<br \/>\n    KEYTRUDA, patients were disease free at study entry (after surgery) with no<br \/>\n    loco-regional relapse or distant metastasis and no clinical evidence of brain<br \/>\n    metastases, patients had a formalin fixed paraffin embedded (FFPE) tumor<br \/>\n    sample available suitable for sequencing, Eastern Cooperative Oncology Group<br \/>\n    (ECOG) Performance Status 0 or 1 and patients with normal organ and marrow<br \/>\n    function reported at screening.\n<\/p>\n<p>\n    <strong>About melanoma<\/strong>\n<\/p>\n<p>\n    Melanoma, the most serious form of skin cancer, is characterized by the<br \/>\n    uncontrolled growth of pigment-producing cells. The rates of melanoma have<br \/>\n    been rising over the past few decades, with more than 330,000 new cases<br \/>\n    diagnosed worldwide in 2022. In the U.S., skin cancer is one of the most<br \/>\n    common types of cancer diagnosed, and melanoma accounts for a large majority<br \/>\n    of skin cancer deaths. It is estimated there will be more than 100,000 new<br \/>\n    cases of melanoma diagnosed and more than 8,000 deaths resulting from the<br \/>\n    disease in the U.S. in 2024.\n<\/p>\n<p>\n    <strong>About KEYTRUDA\u00ae (pembrolizumab) injection, 100 mg<\/strong>\n<\/p>\n<p>\n    KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by<br \/>\n    increasing the ability of the body\u2019s immune system to help detect and fight<br \/>\n    tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the<br \/>\n    interaction between PD-1 and its ligands, PD- L1 and PD-L2, thereby activating<br \/>\n    T lymphocytes which may affect both tumor cells and healthy cells.\n<\/p>\n<p>\n    Merck has the industry\u2019s largest immuno-oncology clinical research program.<br \/>\n    There are currently more than 1,600 trials studying KEYTRUDA across a wide<br \/>\n    variety of cancers and treatment settings. The KEYTRUDA clinical program seeks<br \/>\n    to understand the role of KEYTRUDA across cancers and the factors that may<br \/>\n    predict a patient&#8217;s likelihood of benefitting from treatment with KEYTRUDA,<br \/>\n    including exploring several different biomarkers.\n<\/p>\n<p>\n    <strong>Selected KEYTRUDA\u00ae (pembrolizumab) Indications in the U.S.<\/strong>\n<\/p>\n<p>\n    <i>Melanoma<\/i>\n<\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n    metastatic melanoma.\n<\/p>\n<p>\n    KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12<br \/>\n    years and older) patients with stage IIB, IIC, or III melanoma following<br \/>\n    complete resection.\n<\/p>\n<p><em><br \/>\n        See additional selected KEYTRUDA indications in the U.S. after the Selected<br \/>\n        Important Safety Information.<br \/>\n    <\/em>\n<\/p>\n<p>\n    <strong>Selected Important Safety Information for KEYTRUDA&nbsp;<\/strong>\n<\/p>\n<p>\n    <strong>Severe and Fatal Immune-Mediated Adverse Reactions<\/strong>\n<\/p>\n<p>\n    KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind<br \/>\n    to either the programmed death receptor-1 (PD-1) or the programmed death<br \/>\n    ligand 1 (PD-L1), blocking the PD-1\/PD-L1 pathway, thereby removing inhibition<br \/>\n    of the immune response, potentially breaking peripheral tolerance and inducing<br \/>\n    immune-mediated adverse reactions. Immune-mediated adverse reactions, which<br \/>\n    may be severe or fatal, can occur in any organ system or tissue, can affect<br \/>\n    more than one body system simultaneously, and can occur at any time after<br \/>\n    starting treatment or after discontinuation of treatment. Important<br \/>\n    immune-mediated adverse reactions listed here may not include all possible<br \/>\n    severe and fatal immune-mediated adverse reactions.\n<\/p>\n<p>\n    Monitor patients closely for symptoms and signs that may be clinical<br \/>\n    manifestations of underlying immune-mediated adverse reactions. Early<br \/>\n    identification and management are essential to ensure safe use of<br \/>\n    anti\u2013PD-1\/PD-L1 treatments. Evaluate liver enzymes, creatinine, and thyroid<br \/>\n    function at baseline and periodically during treatment. For patients with TNBC<br \/>\n    treated with KEYTRUDA in the neoadjuvant setting, monitor blood cortisol at<br \/>\n    baseline, prior to surgery, and as clinically indicated. In cases of suspected<br \/>\n    immune-mediated adverse reactions, initiate appropriate workup to exclude<br \/>\n    alternative etiologies, including infection. Institute medical management<br \/>\n    promptly, including specialty consultation as appropriate.\n<\/p>\n<p>\n    Withhold or permanently discontinue KEYTRUDA depending on severity of the<br \/>\n    immune-mediated adverse reaction. In general, if KEYTRUDA requires<br \/>\n    interruption or discontinuation, administer systemic corticosteroid therapy (1<br \/>\n    to 2 mg\/kg\/day prednisone or equivalent) until improvement to Grade 1 or less.<br \/>\n    Upon improvement to Grade 1 or less, initiate corticosteroid taper and<br \/>\n    continue to taper over at least 1 month. Consider administration of other<br \/>\n    systemic immunosuppressants in patients whose adverse reactions are not<br \/>\n    controlled with corticosteroid therapy.&nbsp;\n<\/p>\n<p>\n    <u>Immune-Mediated Pneumonitis<\/u>\n<\/p>\n<p>\n    KEYTRUDA can cause immune-mediated pneumonitis. The incidence is higher in<br \/>\n    patients who have received prior thoracic radiation. Immune-mediated<br \/>\n    pneumonitis occurred in 3.4% (94\/2799) of patients receiving KEYTRUDA,<br \/>\n    including fatal (0.1%), Grade 4 (0.3%), Grade 3 (0.9%), and Grade 2 (1.3%)<br \/>\n    reactions. Systemic corticosteroids were required in 67% (63\/94) of patients.<br \/>\n    Pneumonitis led to permanent discontinuation of KEYTRUDA in 1.3% (36) and<br \/>\n    withholding in 0.9% (26) of patients. All patients who were withheld<br \/>\n    reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence.<br \/>\n    Pneumonitis resolved in 59% of the 94 patients.&nbsp;\n<\/p>\n<p>\n    Pneumonitis occurred in 8% (31\/389) of adult patients with cHL receiving<br \/>\n    KEYTRUDA as a single agent, including Grades 3-4 in 2.3% of patients. Patients<br \/>\n    received high-dose corticosteroids for a median duration of 10 days (range: 2<br \/>\n    days to 53 months). Pneumonitis rates were similar in patients with and<br \/>\n    without prior thoracic radiation. Pneumonitis led to discontinuation of<br \/>\n    KEYTRUDA in 5.4% (21) of patients. Of the patients who developed pneumonitis,<br \/>\n    42% interrupted KEYTRUDA, 68% discontinued KEYTRUDA, and 77% had resolution.&nbsp;\n<\/p>\n<p>\n    Pneumonitis occurred in 7% (41\/580) of adult patients with resected NSCLC who<br \/>\n    received KEYTRUDA as a single agent for adjuvant treatment of NSCLC, including<br \/>\n    fatal (0.2%), Grade 4 (0.3%), and Grade 3 (1%) adverse reactions. Patients<br \/>\n    received high-dose corticosteroids for a median duration of 10 days (range: 1<br \/>\n    day to 2.3 months). Pneumonitis led to discontinuation of KEYTRUDA in 26<br \/>\n    (4.5%) of patients. Of the patients who developed pneumonitis, 54% interrupted<br \/>\n    KEYTRUDA, 63% discontinued KEYTRUDA, and 71% had resolution.\n<\/p>\n<p>\n    <u>Immune-Mediated Colitis<\/u>\n<\/p>\n<p>\n    KEYTRUDA can cause immune-mediated colitis, which may present with diarrhea.<br \/>\n    Cytomegalovirus infection\/reactivation has been reported in patients with<br \/>\n    corticosteroid-refractory immune-mediated colitis. In cases of<br \/>\n    corticosteroid-refractory colitis, consider repeating infectious workup to<br \/>\n    exclude alternative etiologies. Immune-mediated colitis occurred in 1.7%<br \/>\n    (48\/2799) of patients receiving KEYTRUDA, including Grade 4 (&lt;0.1%), Grade<br \/>\n    3 (1.1%), and Grade 2 (0.4%) reactions. Systemic corticosteroids were required<br \/>\n    in 69% (33\/48); additional immunosuppressant therapy was required in 4.2% of<br \/>\n    patients. Colitis led to permanent discontinuation of KEYTRUDA in 0.5% (15)<br \/>\n    and withholding in 0.5% (13) of patients. All patients who were withheld<br \/>\n    reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence.<br \/>\n    Colitis resolved in 85% of the 48 patients.\n<\/p>\n<p>\n    <u>Hepatotoxicity and Immune-Mediated Hepatitis<\/u>\n<\/p>\n<p>\n    <i>KEYTRUDA as a Single Agent<\/i>\n<\/p>\n<p>\n    KEYTRUDA can cause immune-mediated hepatitis. Immune-mediated hepatitis<br \/>\n    occurred in 0.7% (19\/2799) of patients receiving KEYTRUDA, including Grade 4<br \/>\n    (&lt;0.1%), Grade 3 (0.4%), and Grade 2 (0.1%) reactions. Systemic<br \/>\n    corticosteroids were required in 68% (13\/19) of patients; additional<br \/>\n    immunosuppressant therapy was required in 11% of patients. Hepatitis led to<br \/>\n    permanent discontinuation of KEYTRUDA in 0.2% (6) and withholding in 0.3% (9)<br \/>\n    of patients. All patients who were withheld reinitiated KEYTRUDA after symptom<br \/>\n    improvement; of these, none had recurrence. Hepatitis resolved in 79% of the<br \/>\n    19 patients.\n<\/p>\n<p>\n    <i>KEYTRUDA With Axitinib<\/i>\n<\/p>\n<p>\n    KEYTRUDA in combination with axitinib can cause hepatic toxicity. Monitor<br \/>\n    liver enzymes before initiation of and periodically throughout treatment.<br \/>\n    Consider monitoring more frequently as compared to when the drugs are<br \/>\n    administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA<br \/>\n    and axitinib, and consider administering corticosteroids as needed. With the<br \/>\n    combination of KEYTRUDA and axitinib, Grades 3 and 4 increased alanine<br \/>\n    aminotransferase (ALT) (20%) and increased aspartate aminotransferase (AST)<br \/>\n    (13%) were seen at a higher frequency compared to KEYTRUDA alone. Fifty-nine<br \/>\n    percent of the patients with increased ALT received systemic corticosteroids.<br \/>\n    In patients with ALT \u22653 times upper limit of normal (ULN) (Grades 2-4, n=116),<br \/>\n    ALT resolved to Grades 0-1 in 94%. Among the 92 patients who were rechallenged<br \/>\n    with either KEYTRUDA (n=3) or axitinib (n=34) administered as a single agent<br \/>\n    or with both (n=55), recurrence of ALT \u22653 times ULN was observed in 1 patient<br \/>\n    receiving KEYTRUDA, 16 patients receiving axitinib, and 24 patients receiving<br \/>\n    both. All patients with a recurrence of ALT \u22653 ULN subsequently recovered from<br \/>\n    the event.&nbsp;\n<\/p>\n<p>\n    <u>Immune-Mediated Endocrinopathies<\/u>\n<\/p>\n<p>\n    <i>Adrenal Insufficiency<\/i>\n<\/p>\n<p>\n    KEYTRUDA can cause primary or secondary adrenal insufficiency. For Grade 2 or<br \/>\n    higher, initiate symptomatic treatment, including hormone replacement as<br \/>\n    clinically indicated. Withhold KEYTRUDA depending on severity. Adrenal<br \/>\n    insufficiency occurred in 0.8% (22\/2799) of patients receiving KEYTRUDA,<br \/>\n    including Grade 4 (&lt;0.1%), Grade 3 (0.3%), and Grade 2 (0.3%) reactions.<br \/>\n    Systemic corticosteroids were required in 77% (17\/22) of patients; of these,<br \/>\n    the majority remained on systemic corticosteroids. Adrenal insufficiency led<br \/>\n    to permanent discontinuation of KEYTRUDA in &lt;0.1% (1) and withholding in<br \/>\n    0.3% (8) of patients. All patients who were withheld reinitiated KEYTRUDA<br \/>\n    after symptom improvement.&nbsp;\n<\/p>\n<p>\n    <i>Hypophysitis<\/i>\n<\/p>\n<p>\n    KEYTRUDA can cause immune-mediated hypophysitis. Hypophysitis can present with<br \/>\n    acute symptoms associated with mass effect such as headache, photophobia, or<br \/>\n    visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone<br \/>\n    replacement as indicated. Withhold or permanently discontinue KEYTRUDA<br \/>\n    depending on severity. Hypophysitis occurred in 0.6% (17\/2799) of patients<br \/>\n    receiving KEYTRUDA, including Grade 4 (&lt;0.1%), Grade 3 (0.3%), and Grade 2<br \/>\n    (0.2%) reactions. Systemic corticosteroids were required in 94% (16\/17) of<br \/>\n    patients; of these, the majority remained on systemic corticosteroids.<br \/>\n    Hypophysitis led to permanent discontinuation of KEYTRUDA in 0.1% (4) and<br \/>\n    withholding in 0.3% (7) of patients. All patients who were withheld<br \/>\n    reinitiated KEYTRUDA after symptom improvement.\n<\/p>\n<p>\n    <i>Thyroid Disorders<\/i>\n<\/p>\n<p>\n    KEYTRUDA can cause immune-mediated thyroid disorders. Thyroiditis can present<br \/>\n    with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism.<br \/>\n    Initiate hormone replacement for hypothyroidism or institute medical<br \/>\n    management of hyperthyroidism as clinically indicated. Withhold or permanently<br \/>\n    discontinue KEYTRUDA depending on severity. Thyroiditis occurred in 0.6%<br \/>\n    (16\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.3%). None<br \/>\n    discontinued, but KEYTRUDA was withheld in &lt;0.1% (1) of patients.\n<\/p>\n<p>\n    Hyperthyroidism occurred in 3.4% (96\/2799) of patients receiving KEYTRUDA,<br \/>\n    including Grade 3 (0.1%) and Grade 2 (0.8%). It led to permanent<br \/>\n    discontinuation of KEYTRUDA in &lt;0.1% (2) and withholding in 0.3% (7) of<br \/>\n    patients. All patients who were withheld reinitiated KEYTRUDA after symptom<br \/>\n    improvement. Hypothyroidism occurred in 8% (237\/2799) of patients receiving<br \/>\n    KEYTRUDA, including Grade 3 (0.1%) and Grade 2 (6.2%). It led to permanent<br \/>\n    discontinuation of KEYTRUDA in &lt;0.1% (1) and withholding in 0.5% (14) of<br \/>\n    patients. All patients who were withheld reinitiated KEYTRUDA after symptom<br \/>\n    improvement. The majority of patients with hypothyroidism required long-term<br \/>\n    thyroid hormone replacement. The incidence of new or worsening hypothyroidism<br \/>\n    was higher in 1185 patients with HNSCC, occurring in 16% of patients receiving<br \/>\n    KEYTRUDA as a single agent or in combination with platinum and FU, including<br \/>\n    Grade 3 (0.3%) hypothyroidism. The incidence of new or worsening<br \/>\n    hypothyroidism was higher in 389 adult patients with cHL (17%) receiving<br \/>\n    KEYTRUDA as a single agent, including Grade 1 (6.2%) and Grade 2 (10.8%)<br \/>\n    hypothyroidism. The incidence of new or worsening hyperthyroidism was higher<br \/>\n    in 580 patients with resected NSCLC, occurring in 11% of patients receiving<br \/>\n    KEYTRUDA as a single agent as adjuvant treatment, including Grade 3 (0.2%)<br \/>\n    hyperthyroidism. The incidence of new or worsening hypothyroidism was higher<br \/>\n    in 580 patients with resected NSCLC, occurring in 22% of patients receiving<br \/>\n    KEYTRUDA as a single agent as adjuvant treatment (KEYNOTE-091), including<br \/>\n    Grade 3 (0.3%) hypothyroidism.\n<\/p>\n<p>\n    <i><br \/>\n        Type 1 Diabetes Mellitus (DM), Which Can Present With Diabetic Ketoacidosis<br \/>\n    <\/i>\n<\/p>\n<p>\n    Monitor patients for hyperglycemia or other signs and symptoms of diabetes.<br \/>\n    Initiate treatment with insulin as clinically indicated. Withhold KEYTRUDA<br \/>\n    depending on severity. Type 1 DM occurred in 0.2% (6\/2799) of patients<br \/>\n    receiving KEYTRUDA. It led to permanent discontinuation in &lt;0.1% (1) and<br \/>\n    withholding of KEYTRUDA in &lt;0.1% (1) of patients. All patients who were<br \/>\n    withheld reinitiated KEYTRUDA after symptom improvement.\n<\/p>\n<p>\n    <u>Immune-Mediated Nephritis With Renal Dysfunction<\/u>\n<\/p>\n<p>\n    KEYTRUDA can cause immune-mediated nephritis. Immune-mediated nephritis<br \/>\n    occurred in 0.3% (9\/2799) of patients receiving KEYTRUDA, including Grade 4<br \/>\n    (&lt;0.1%), Grade 3 (0.1%), and Grade 2 (0.1%) reactions. Systemic<br \/>\n    corticosteroids were required in 89% (8\/9) of patients. Nephritis led to<br \/>\n    permanent discontinuation of KEYTRUDA in 0.1% (3) and withholding in 0.1% (3)<br \/>\n    of patients. All patients who were withheld reinitiated KEYTRUDA after symptom<br \/>\n    improvement; of these, none had recurrence. Nephritis resolved in 56% of the 9<br \/>\n    patients.\n<\/p>\n<p>\n    <u>Immune-Mediated Dermatologic Adverse Reactions<\/u>\n<\/p>\n<p>\n    KEYTRUDA can cause immune-mediated rash or dermatitis. Exfoliative dermatitis,<br \/>\n    including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic<br \/>\n    symptoms, and toxic epidermal necrolysis, has occurred with anti\u2013PD-1\/PD-L1<br \/>\n    treatments. Topical emollients and\/or topical corticosteroids may be adequate<br \/>\n    to treat mild to moderate nonexfoliative rashes. Withhold or permanently<br \/>\n    discontinue KEYTRUDA depending on severity. Immune-mediated dermatologic<br \/>\n    adverse reactions occurred in 1.4% (38\/2799) of patients receiving KEYTRUDA,<br \/>\n    including Grade 3 (1%) and Grade 2 (0.1%) reactions. Systemic corticosteroids<br \/>\n    were required in 40% (15\/38) of patients. These reactions led to permanent<br \/>\n    discontinuation in 0.1% (2) and withholding of KEYTRUDA in 0.6% (16) of<br \/>\n    patients. All patients who were withheld reinitiated KEYTRUDA after symptom<br \/>\n    improvement; of these, 6% had recurrence. The reactions resolved in 79% of the<br \/>\n    38 patients\n<\/p>\n<p>\n    <u>Other Immune-Mediated Adverse Reactions<\/u>\n<\/p>\n<p>\n    The following clinically significant immune-mediated adverse reactions<br \/>\n    occurred at an incidence of &lt;1% (unless otherwise noted) in patients who<br \/>\n    received KEYTRUDA or were reported with the use of other anti\u2013PD-1\/PD-L1<br \/>\n    treatments. Severe or fatal cases have been reported for some of these adverse<br \/>\n    reactions. Cardiac\/Vascular: Myocarditis, pericarditis, vasculitis; Nervous<br \/>\n    System: Meningitis, encephalitis, myelitis and demyelination, myasthenic<br \/>\n    syndrome\/myasthenia gravis (including exacerbation), Guillain-Barr\u00e9 syndrome,<br \/>\n    nerve paresis, autoimmune neuropathy; Ocular: Uveitis, iritis and other ocular<br \/>\n    inflammatory toxicities can occur. Some cases can be associated with retinal<br \/>\n    detachment. Various grades of visual impairment, including blindness, can<br \/>\n    occur. If uveitis occurs in combination with other immune-mediated adverse<br \/>\n    reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require<br \/>\n    treatment with systemic steroids to reduce the risk of permanent vision loss;<br \/>\n    Gastrointestinal: Pancreatitis, to include increases in serum amylase and<br \/>\n    lipase levels, gastritis, duodenitis; Musculoskeletal and Connective Tissue:<br \/>\n    Myositis\/polymyositis, rhabdomyolysis (and associated sequelae, including<br \/>\n    renal failure), arthritis (1.5%), polymyalgia rheumatica; Endocrine:<br \/>\n    Hypoparathyroidism; Hematologic\/Immune: Hemolytic anemia, aplastic anemia,<br \/>\n    hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome,<br \/>\n    histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis,<br \/>\n    immune thrombocytopenic purpura, solid organ transplant rejection, other<br \/>\n    transplant (including corneal graft) rejection.\n<\/p>\n<p>\n    <strong>Infusion-Related Reactions<\/strong>\n<\/p>\n<p>\n    KEYTRUDA can cause severe or life-threatening infusion-related reactions,<br \/>\n    including hypersensitivity and anaphylaxis, which have been reported in 0.2%<br \/>\n    of 2799 patients receiving KEYTRUDA. Monitor for signs and symptoms of<br \/>\n    infusion-related reactions. Interrupt or slow the rate of infusion for Grade 1<br \/>\n    or Grade 2 reactions. For Grade 3 or Grade 4 reactions, stop infusion and<br \/>\n    permanently discontinue KEYTRUDA.\n<\/p>\n<p>\n    <strong><br \/>\n        Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)<br \/>\n    <\/strong>\n<\/p>\n<p>\n    Fatal and other serious complications can occur in patients who receive<br \/>\n    allogeneic HSCT before or after anti\u2013PD-1\/PD-L1 treatments. Transplant-related<br \/>\n    complications include hyperacute graft-versus-host disease (GVHD), acute and<br \/>\n    chronic GVHD, hepatic veno-occlusive disease after reduced intensity<br \/>\n    conditioning, and steroid-requiring febrile syndrome (without an identified<br \/>\n    infectious cause). These complications may occur despite intervening therapy<br \/>\n    between anti\u2013PD-1\/PD-L1 treatment and allogeneic HSCT. Follow patients closely<br \/>\n    for evidence of these complications and intervene promptly. Consider the<br \/>\n    benefit vs risks of using anti\u2013PD-1\/PD-L1 treatments prior to or after an<br \/>\n    allogeneic HSCT.\n<\/p>\n<p>\n    <strong>Increased Mortality in Patients With Multiple Myeloma<\/strong>\n<\/p>\n<p>\n    In trials in patients with multiple myeloma, the addition of KEYTRUDA to a<br \/>\n    thalidomide analogue plus dexamethasone resulted in increased mortality.<br \/>\n    Treatment of these patients with an anti\u2013PD-1\/PD-L1 treatment in this<br \/>\n    combination is not recommended outside of controlled trials.\n<\/p>\n<p>\n    <strong>Embryofetal Toxicity<\/strong>\n<\/p>\n<p>\n    Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n    administered to a pregnant woman. Advise women of this potential risk. In<br \/>\n    females of reproductive potential, verify pregnancy status prior to initiating<br \/>\n    KEYTRUDA and advise them to use effective contraception during treatment and<br \/>\n    for 4 months after the last dose.\n<\/p>\n<p>\n    <strong>Adverse Reactions<\/strong>\n<\/p>\n<p>\n    In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9% of<br \/>\n    555 patients with advanced melanoma; adverse reactions leading to permanent<br \/>\n    discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n    hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and cardiac<br \/>\n    failure (0.4%). The most common adverse reactions (\u226520%) with KEYTRUDA were<br \/>\n    fatigue (28%), diarrhea (26%), rash (24%), and nausea (21%).\n<\/p>\n<p>\n    In KEYNOTE-054, when KEYTRUDA was administered as a single agent to patients<br \/>\n    with stage III melanoma, KEYTRUDA was permanently discontinued due to adverse<br \/>\n    reactions in 14% of 509 patients; the most common (\u22651%) were pneumonitis<br \/>\n    (1.4%), colitis (1.2%), and diarrhea (1%). Serious adverse reactions occurred<br \/>\n    in 25% of patients receiving KEYTRUDA. The most common adverse reaction (\u226520%)<br \/>\n    with KEYTRUDA was diarrhea (28%). In KEYNOTE-716, when KEYTRUDA was<br \/>\n    administered as a single agent to patients with stage IIB or IIC melanoma,<br \/>\n    adverse reactions occurring in patients with stage IIB or IIC melanoma were<br \/>\n    similar to those occurring in 1011 patients with stage III melanoma from<br \/>\n    KEYNOTE-054.\n<\/p>\n<p>\n    In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and platinum<br \/>\n    chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was discontinued due to<br \/>\n    adverse reactions in 20% of 405 patients. The most common adverse reactions<br \/>\n    resulting in permanent discontinuation of KEYTRUDA were pneumonitis (3%) and<br \/>\n    acute kidney injury (2%). The most common adverse reactions (\u226520%) with<br \/>\n    KEYTRUDA were nausea (56%), fatigue (56%), constipation (35%), diarrhea (31%),<br \/>\n    decreased appetite (28%), rash (25%), vomiting (24%), cough (21%), dyspnea<br \/>\n    (21%), and pyrexia (20%).\n<\/p>\n<p>\n    In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and either<br \/>\n    paclitaxel or paclitaxel protein-bound in metastatic squamous NSCLC, KEYTRUDA<br \/>\n    was discontinued due to adverse reactions in 15% of 101 patients. The most<br \/>\n    frequent serious adverse reactions reported in at least 2% of patients were<br \/>\n    febrile neutropenia, pneumonia, and urinary tract infection. Adverse reactions<br \/>\n    observed in KEYNOTE-407 were similar to those observed in KEYNOTE-189 with the<br \/>\n    exception that increased incidences of alopecia (47% vs 36%) and peripheral<br \/>\n    neuropathy (31% vs 25%) were observed in the KEYTRUDA and chemotherapy arm<br \/>\n    compared to the placebo and chemotherapy arm in KEYNOTE-407.\n<\/p>\n<p>\n    In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in 19% of<br \/>\n    636 patients with advanced NSCLC; the most common were pneumonitis (3%), death<br \/>\n    due to unknown cause (1.6%), and pneumonia (1.4%). The most frequent serious<br \/>\n    adverse reactions reported in at least 2% of patients were pneumonia (7%),<br \/>\n    pneumonitis (3.9%), pulmonary embolism (2.4%), and pleural effusion (2.2%).<br \/>\n    The most common adverse reaction (\u226520%) was fatigue (25%).\n<\/p>\n<p>\n    In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse reactions<br \/>\n    in 8% of 682 patients with metastatic NSCLC; the most common was pneumonitis<br \/>\n    (1.8%). The most common adverse reactions (\u226520%) were decreased appetite<br \/>\n    (25%), fatigue (25%), dyspnea (23%), and nausea (20%).\n<\/p>\n<p>\n    In KEYNOTE-671, adverse reactions occurring in patients with resectable NSCLC<br \/>\n    receiving KEYTRUDA in combination with platinum-containing chemotherapy, given<br \/>\n    as neoadjuvant treatment and continued as single-agent adjuvant treatment,<br \/>\n    were generally similar to those occurring in patients in other clinical trials<br \/>\n    across tumor types receiving KEYTRUDA in combination with chemotherapy.\n<\/p>\n<p>\n    The most common adverse reactions (reported in \u226520%) in patients receiving<br \/>\n    KEYTRUDA in combination with chemotherapy were fatigue\/asthenia, nausea,<br \/>\n    constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea,<br \/>\n    pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, stomatitis,<br \/>\n    headache, weight loss, abdominal pain, arthralgia, myalgia, insomnia,<br \/>\n    palmar-plantar erythrodysesthesia, urinary tract infection, and<br \/>\n    hypothyroidism.\n<\/p>\n<p>\n    In the neoadjuvant phase of KEYNOTE-671, when KEYTRUDA was administered in<br \/>\n    combination with platinum-containing chemotherapy as neoadjuvant treatment,<br \/>\n    serious adverse reactions occurred in 34% of 396 patients. The most frequent<br \/>\n    (\u22652%) serious adverse reactions were pneumonia (4.8%), venous thromboembolism<br \/>\n    (3.3%), and anemia (2%). Fatal adverse reactions occurred in 1.3% of patients,<br \/>\n    including death due to unknown cause (0.8%), sepsis (0.3%), and<br \/>\n    immune-mediated lung disease (0.3%). Permanent discontinuation of any study<br \/>\n    drug due to an adverse reaction occurred in 18% of patients who received<br \/>\n    KEYTRUDA in combination with platinum-containing chemotherapy; the most<br \/>\n    frequent adverse reactions (\u22651%) that led to permanent discontinuation of any<br \/>\n    study drug were acute kidney injury (1.8%), interstitial lung disease (1.8%),<br \/>\n    anemia (1.5%), neutropenia (1.5%) and pneumonia (1.3%).\n<\/p>\n<p>\n    Of the KEYTRUDA-treated patients who received neoadjuvant treatment, 6% of 396<br \/>\n    patients did not receive surgery due to adverse reactions. The most frequent<br \/>\n    (\u22651%) adverse reaction that led to cancellation of surgery in the KEYTRUDA arm<br \/>\n    was interstitial lung disease (1%).\n<\/p>\n<p>\n    In the adjuvant phase of KEYNOTE-671, when KEYTRUDA was administered as a<br \/>\n    single agent as adjuvant treatment, serious adverse reactions occurred in 14%<br \/>\n    of 290 patients. The most frequent serious adverse reaction was pneumonia<br \/>\n    (3.4%). One fatal adverse reaction of pulmonary hemorrhage occurred. Permanent<br \/>\n    discontinuation of KEYTRUDA due to an adverse reaction occurred in 12% of<br \/>\n    patients who received KEYTRUDA as a single agent, given as adjuvant treatment;<br \/>\n    the most frequent adverse reactions (\u22651%) that led to permanent<br \/>\n    discontinuation of KEYTRUDA were diarrhea (1.7%), interstitial lung disease<br \/>\n    (1.4%), increased aspartate aminotransferase (1%), and musculoskeletal pain<br \/>\n    (1%).\n<\/p>\n<p>\n    Adverse reactions observed in KEYNOTE-091 were generally similar to those<br \/>\n    occurring in other patients with NSCLC receiving KEYTRUDA as a single agent,<br \/>\n    with the exception of hypothyroidism (22%), hyperthyroidism (11%), and<br \/>\n    pneumonitis (7%). Two fatal adverse reactions of myocarditis occurred.\n<\/p>\n<p>\n    In KEYNOTE-048, KEYTRUDA monotherapy was discontinued due to adverse events in<br \/>\n    12% of 300 patients with HNSCC; the most common adverse reactions leading to<br \/>\n    permanent discontinuation were sepsis (1.7%) and pneumonia (1.3%). The most<br \/>\n    common adverse reactions (\u226520%) were fatigue (33%), constipation (20%), and<br \/>\n    rash (20%).\n<\/p>\n<p>\n    In KEYNOTE-048, when KEYTRUDA was administered in combination with platinum<br \/>\n    (cisplatin or carboplatin) and FU chemotherapy, KEYTRUDA was discontinued due<br \/>\n    to adverse reactions in 16% of 276 patients with HNSCC. The most common<br \/>\n    adverse reactions resulting in permanent discontinuation of KEYTRUDA were<br \/>\n    pneumonia (2.5%), pneumonitis (1.8%), and septic shock (1.4%). The most common<br \/>\n    adverse reactions (\u226520%) were nausea (51%), fatigue (49%), constipation (37%),<br \/>\n    vomiting (32%), mucosal inflammation (31%), diarrhea (29%), decreased appetite<br \/>\n    (29%), stomatitis (26%), and cough (22%).\n<\/p>\n<p>\n    In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in 17% of<br \/>\n    192 patients with HNSCC. Serious adverse reactions occurred in 45% of<br \/>\n    patients. The most frequent serious adverse reactions reported in at least 2%<br \/>\n    of patients were pneumonia, dyspnea, confusional state, vomiting, pleural<br \/>\n    effusion, and respiratory failure. The most common adverse reactions (\u226520%)<br \/>\n    were fatigue, decreased appetite, and dyspnea. Adverse reactions occurring in<br \/>\n    patients with HNSCC were generally similar to those occurring in patients with<br \/>\n    melanoma or NSCLC who received KEYTRUDA as a monotherapy, with the exception<br \/>\n    of increased incidences of facial edema and new or worsening hypothyroidism.\n<\/p>\n<p>\n    In KEYNOTE-204, KEYTRUDA was discontinued due to adverse reactions in 14% of<br \/>\n    148 patients with cHL. Serious adverse reactions occurred in 30% of patients<br \/>\n    receiving KEYTRUDA; those \u22651% were pneumonitis, pneumonia, pyrexia,<br \/>\n    myocarditis, acute kidney injury, febrile neutropenia, and sepsis. Three<br \/>\n    patients died from causes other than disease progression: 2 from complications<br \/>\n    after allogeneic HSCT and 1 from unknown cause. The most common adverse<br \/>\n    reactions (\u226520%) were upper respiratory tract infection (41%), musculoskeletal<br \/>\n    pain (32%), diarrhea (22%), and pyrexia, fatigue, rash, and cough (20% each).\n<\/p>\n<p>\n    In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5% of<br \/>\n    210 patients with cHL. Serious adverse reactions occurred in 16% of patients;<br \/>\n    those \u22651% were pneumonia, pneumonitis, pyrexia, dyspnea, GVHD, and herpes<br \/>\n    zoster. Two patients died from causes other than disease progression: 1 from<br \/>\n    GVHD after subsequent allogeneic HSCT and 1 from septic shock. The most common<br \/>\n    adverse reactions (\u226520%) were fatigue (26%), pyrexia (24%), cough (24%),<br \/>\n    musculoskeletal pain (21%), diarrhea (20%), and rash (20%).\n<\/p>\n<p>\n    In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8% of 53<br \/>\n    patients with PMBCL. Serious adverse reactions occurred in 26% of patients and<br \/>\n    included arrhythmia (4%), cardiac tamponade (2%), myocardial infarction (2%),<br \/>\n    pericardial effusion (2%), and pericarditis (2%). Six (11%) patients died<br \/>\n    within 30 days of start of treatment. The most common adverse reactions (\u226520%)<br \/>\n    were musculoskeletal pain (30%), upper respiratory tract infection and pyrexia<br \/>\n    (28% each), cough (26%), fatigue (23%), and dyspnea (21%).\n<\/p>\n<p>\n    In KEYNOTE-A39, when KEYTRUDA was administered in combination with enfortumab<br \/>\n    vedotin to patients with locally advanced or metastatic urothelial cancer<br \/>\n    (n=440), fatal adverse reactions occurred in 3.9% of patients, including acute<br \/>\n    respiratory failure (0.7%), pneumonia (0.5%), and pneumonitis\/ILD (0.2%).<br \/>\n    Serious adverse reactions occurred in 50% of patients receiving KEYTRUDA in<br \/>\n    combination with enfortumab vedotin; the serious adverse reactions in \u22652% of<br \/>\n    patients were rash (6%), acute kidney injury (5%), pneumonitis\/ILD (4.5%),<br \/>\n    urinary tract infection (3.6%), diarrhea (3.2%), pneumonia (2.3%), pyrexia<br \/>\n    (2%), and hyperglycemia (2%). Permanent discontinuation of KEYTRUDA occurred<br \/>\n    in 27% of patients. The most common adverse reactions (\u22652%) resulting in<br \/>\n    permanent discontinuation of KEYTRUDA were pneumonitis\/ILD (4.8%) and rash<br \/>\n    (3.4%). The most common adverse reactions (\u226520%) occurring in patients treated<br \/>\n    with KEYTRUDA in combination with enfortumab vedotin were rash (68%),<br \/>\n    peripheral neuropathy (67%), fatigue (51%), pruritus (41%), diarrhea (38%),<br \/>\n    alopecia (35%), weight loss (33%), decreased appetite (33%), nausea (26%),<br \/>\n    constipation (26%), dry eye (24%), dysgeusia (21%), and urinary tract<br \/>\n    infection (21%).\n<\/p>\n<p>\n    In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in 11% of<br \/>\n    370 patients with locally advanced or metastatic urothelial carcinoma. Serious<br \/>\n    adverse reactions occurred in 42% of patients; those \u22652% were urinary tract<br \/>\n    infection, hematuria, acute kidney injury, pneumonia, and urosepsis. The most<br \/>\n    common adverse reactions (\u226520%) were fatigue (38%), musculoskeletal pain<br \/>\n    (24%), decreased appetite (22%), constipation (21%), rash (21%), and diarrhea<br \/>\n    (20%).\n<\/p>\n<p>\n    In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8% of<br \/>\n    266 patients with locally advanced or metastatic urothelial carcinoma. The<br \/>\n    most common adverse reaction resulting in permanent discontinuation of<br \/>\n    KEYTRUDA was pneumonitis (1.9%). Serious adverse reactions occurred in 39% of<br \/>\n    KEYTRUDA-treated patients; those \u22652% were urinary tract infection, pneumonia,<br \/>\n    anemia, and pneumonitis. The most common adverse reactions (\u226520%) in patients<br \/>\n    who received KEYTRUDA were fatigue (38%), musculoskeletal pain (32%), pruritus<br \/>\n    (23%), decreased appetite (21%), nausea (21%), and rash (20%).\n<\/p>\n<p>\n    In KEYNOTE-057, KEYTRUDA was discontinued due to adverse reactions in 11% of<br \/>\n    148 patients with high-risk NMIBC. The most common adverse reaction resulting<br \/>\n    in permanent discontinuation of KEYTRUDA was pneumonitis (1.4%). Serious<br \/>\n    adverse reactions occurred in 28% of patients; those \u22652% were pneumonia (3%),<br \/>\n    cardiac ischemia (2%), colitis (2%), pulmonary embolism (2%), sepsis (2%), and<br \/>\n    urinary tract infection (2%). The most common adverse reactions (\u226520%) were<br \/>\n    fatigue (29%), diarrhea (24%), and rash (24%).\n<\/p>\n<p>\n    Adverse reactions occurring in patients with MSI-H or dMMR CRC were similar to<br \/>\n    those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a<br \/>\n    monotherapy.\n<\/p>\n<p>\n    In KEYNOTE-158 and KEYNOTE-164, adverse reactions occurring in patients with<br \/>\n    MSI-H or dMMR cancer were similar to those occurring in patients with other<br \/>\n    solid tumors who received KEYTRUDA as a single agent.\n<\/p>\n<p>\n    In KEYNOTE-811, when KEYTRUDA was administered in combination with<br \/>\n    trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, KEYTRUDA<br \/>\n    was discontinued due to adverse reactions in 6% of 217 patients with locally<br \/>\n    advanced unresectable or metastatic HER2+ gastric or GEJ adenocarcinoma. The<br \/>\n    most common adverse reaction resulting in permanent discontinuation was<br \/>\n    pneumonitis (1.4%). In the KEYTRUDA arm versus placebo, there was a difference<br \/>\n    of \u22655% incidence between patients treated with KEYTRUDA versus standard of<br \/>\n    care for diarrhea (53% vs 44%) and nausea (49% vs 44%).\n<\/p>\n<p>\n    In KEYNOTE-859, when KEYTRUDA was administered in combination with<br \/>\n    fluoropyrimidine- and platinum-containing chemotherapy, serious adverse<br \/>\n    reactions occurred in 45% of 785 patients. Serious adverse reactions in &gt;2% of<br \/>\n    patients included pneumonia (4.1%), diarrhea (3.9%), hemorrhage (3.9%), and<br \/>\n    vomiting (2.4%). Fatal adverse reactions occurred in 8% of patients who<br \/>\n    received KEYTRUDA including infection (2.3%) and thromboembolism (1.3%).<br \/>\n    KEYTRUDA was permanently discontinued due to adverse reactions in 15% of<br \/>\n    patients. The most common adverse reactions resulting in permanent<br \/>\n    discontinuation of KEYTRUDA (\u22651%) were infections (1.8%) and diarrhea (1.0%).<br \/>\n    The most common adverse reactions (reported in \u226520%) in patients receiving<br \/>\n    KEYTRUDA in combination with chemotherapy were peripheral neuropathy (47%),<br \/>\n    nausea (46%), fatigue (40%), diarrhea (36%), vomiting (34%), decreased<br \/>\n    appetite (29%), abdominal pain (26%), palmar-plantar erythrodysesthesia<br \/>\n    syndrome (25%), constipation (22%), and weight loss (20%).\n<\/p>\n<p>\n    In KEYNOTE-590, when KEYTRUDA was administered with cisplatin and fluorouracil<br \/>\n    to patients with metastatic or locally advanced esophageal or GEJ (tumors with<br \/>\n    epicenter 1 to 5 centimeters above the GEJ) carcinoma who were not candidates<br \/>\n    for surgical resection or definitive chemoradiation, KEYTRUDA was discontinued<br \/>\n    due to adverse reactions in 15% of 370 patients. The most common adverse<br \/>\n    reactions resulting in permanent discontinuation of KEYTRUDA (\u22651%) were<br \/>\n    pneumonitis (1.6%), acute kidney injury (1.1%), and pneumonia (1.1%). The most<br \/>\n    common adverse reactions (\u226520%) with KEYTRUDA in combination with chemotherapy<br \/>\n    were nausea (67%), fatigue (57%), decreased appetite (44%), constipation<br \/>\n    (40%), diarrhea (36%), vomiting (34%), stomatitis (27%), and weight loss<br \/>\n    (24%).\n<\/p>\n<p>\n    Adverse reactions occurring in patients with esophageal cancer who received<br \/>\n    KEYTRUDA as a monotherapy were similar to those occurring in patients with<br \/>\n    melanoma or NSCLC who received KEYTRUDA as a monotherapy.\n<\/p>\n<p>\n    In KEYNOTE-A18, when KEYTRUDA was administered with CRT (cisplatin plus<br \/>\n    external beam radiation therapy [EBRT] followed by brachytherapy [BT]) to<br \/>\n    patients with FIGO 2014 Stage III-IVA cervical cancer, fatal adverse reactions<br \/>\n    occurred in 1.4% of 292 patients, including 1 case each (0.3%) of large<br \/>\n    intestinal perforation, urosepsis, sepsis, and vaginal hemorrhage. Serious<br \/>\n    adverse reactions occurred in 30% of patients; those \u22651% included urinary<br \/>\n    tract infection (2.7%), urosepsis (1.4%), and sepsis (1%). KEYTRUDA was<br \/>\n    discontinued for adverse reactions in 7% of patients. The most common adverse<br \/>\n    reaction (\u22651%) resulting in permanent discontinuation was diarrhea (1%). For<br \/>\n    patients treated with KEYTRUDA in combination with CRT, the most common<br \/>\n    adverse reactions (\u226510%) were nausea (56%), diarrhea (50%), vomiting (33%),<br \/>\n    urinary tract infection (32%), fatigue (26%), hypothyroidism (20%),<br \/>\n    constipation (18%), decreased appetite and weight loss (17% each), abdominal<br \/>\n    pain and pyrexia (12% each), hyperthyroidism, dysuria, rash (11% each), and<br \/>\n    pelvic pain (10%).\n<\/p>\n<p>\n    In KEYNOTE-826, when KEYTRUDA was administered in combination with paclitaxel<br \/>\n    and cisplatin or paclitaxel and carboplatin, with or without bevacizumab<br \/>\n    (n=307), to patients with persistent, recurrent, or first-line metastatic<br \/>\n    cervical cancer regardless of tumor PD-L1 expression who had not been treated<br \/>\n    with chemotherapy except when used concurrently as a radio-sensitizing agent,<br \/>\n    fatal adverse reactions occurred in 4.6% of patients, including 3 cases of<br \/>\n    hemorrhage, 2 cases each of sepsis and due to unknown causes, and 1 case each<br \/>\n    of acute myocardial infarction, autoimmune encephalitis, cardiac arrest,<br \/>\n    cerebrovascular accident, femur fracture with perioperative pulmonary embolus,<br \/>\n    intestinal perforation, and pelvic infection. Serious adverse reactions<br \/>\n    occurred in 50% of patients receiving KEYTRUDA in combination with<br \/>\n    chemotherapy with or without bevacizumab; those \u22653% were febrile neutropenia<br \/>\n    (6.8%), urinary tract infection (5.2%), anemia (4.6%), and acute kidney injury<br \/>\n    and sepsis (3.3% each).\n<\/p>\n<p>\n    KEYTRUDA was discontinued in 15% of patients due to adverse reactions. The<br \/>\n    most common adverse reaction resulting in permanent discontinuation (\u22651%) was<br \/>\n    colitis (1%).\n<\/p>\n<p>\n    For patients treated with KEYTRUDA, chemotherapy, and bevacizumab (n=196), the<br \/>\n    most common adverse reactions (\u226520%) were peripheral neuropathy (62%),<br \/>\n    alopecia (58%), anemia (55%), fatigue\/asthenia (53%), nausea and neutropenia<br \/>\n    (41% each), diarrhea (39%), hypertension and thrombocytopenia (35% each),<br \/>\n    constipation and arthralgia (31% each), vomiting (30%), urinary tract<br \/>\n    infection (27%), rash (26%), leukopenia (24%), hypothyroidism (22%), and<br \/>\n    decreased appetite (21%).\n<\/p>\n<p>\n    For patients treated with KEYTRUDA in combination with chemotherapy with or<br \/>\n    without bevacizumab, the most common adverse reactions (\u226520%) were peripheral<br \/>\n    neuropathy (58%), alopecia (56%), fatigue (47%), nausea (40%), diarrhea (36%),<br \/>\n    constipation (28%), arthralgia (27%), vomiting (26%), hypertension and urinary<br \/>\n    tract infection (24% each), and rash (22%).\n<\/p>\n<p>\n    In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8% of 98<br \/>\n    patients with previously treated recurrent or metastatic cervical cancer.<br \/>\n    Serious adverse reactions occurred in 39% of patients receiving KEYTRUDA; the<br \/>\n    most frequent included anemia (7%), fistula, hemorrhage, and infections<br \/>\n    [except urinary tract infections] (4.1% each). The most common adverse<br \/>\n    reactions (\u226520%) were fatigue (43%), musculoskeletal pain (27%), diarrhea<br \/>\n    (23%), pain and abdominal pain (22% each), and decreased appetite (21%).\n<\/p>\n<p>\n    In KEYNOTE-394, KEYTRUDA was discontinued due to adverse reactions in 13% of<br \/>\n    299 patients with previously treated hepatocellular carcinoma. The most common<br \/>\n    adverse reaction resulting in permanent discontinuation of KEYTRUDA was<br \/>\n    ascites (2.3%). The most common adverse reactions in patients receiving<br \/>\n    KEYTRUDA (\u226510%) were pyrexia (18%), rash (18%), diarrhea (16%), decreased<br \/>\n    appetite (15%), pruritus (12%), upper respiratory tract infection (11%), cough<br \/>\n    (11%), and hypothyroidism (10%).\n<\/p>\n<p>\n    In KEYNOTE-966, when KEYTRUDA was administered in combination with gemcitabine<br \/>\n    and cisplatin, KEYTRUDA was discontinued for adverse reactions in 15% of 529<br \/>\n    patients with locally advanced unresectable or metastatic biliary tract<br \/>\n    cancer. The most common adverse reaction resulting in permanent<br \/>\n    discontinuation of KEYTRUDA (\u22651%) was pneumonitis (1.3%). Adverse reactions<br \/>\n    leading to the interruption of KEYTRUDA occurred in 55% of patients. The most<br \/>\n    common adverse reactions or laboratory abnormalities leading to interruption<br \/>\n    of KEYTRUDA (\u22652%) were decreased neutrophil count (18%), decreased platelet<br \/>\n    count (10%), anemia (6%), decreased white blood cell count (4%), pyrexia<br \/>\n    (3.8%), fatigue (3.0%), cholangitis (2.8%), increased ALT (2.6%), increased<br \/>\n    AST (2.5%), and biliary obstruction (2.3%).\n<\/p>\n<p>\n    In KEYNOTE-017 and KEYNOTE-913, adverse reactions occurring in patients with<br \/>\n    MCC (n=105) were generally similar to those occurring in patients with<br \/>\n    melanoma or NSCLC who received KEYTRUDA as a single agent.\n<\/p>\n<p>\n    In KEYNOTE-426, when KEYTRUDA was administered in combination with axitinib,<br \/>\n    fatal adverse reactions occurred in 3.3% of 429 patients. Serious adverse<br \/>\n    reactions occurred in 40% of patients, the most frequent (\u22651%) were<br \/>\n    hepatotoxicity (7%), diarrhea (4.2%), acute kidney injury (2.3%), dehydration<br \/>\n    (1%), and pneumonitis (1%). Permanent discontinuation due to an adverse<br \/>\n    reaction occurred in 31% of patients; KEYTRUDA only (13%), axitinib only<br \/>\n    (13%), and the combination (8%); the most common were hepatotoxicity (13%),<br \/>\n    diarrhea\/colitis (1.9%), acute kidney injury (1.6%), and cerebrovascular<br \/>\n    accident (1.2%). The most common adverse reactions (\u226520%) were diarrhea (56%),<br \/>\n    fatigue\/asthenia (52%), hypertension (48%), hepatotoxicity (39%),<br \/>\n    hypothyroidism (35%), decreased appetite (30%), palmar-plantar<br \/>\n    erythrodysesthesia (28%), nausea (28%), stomatitis\/mucosal inflammation (27%),<br \/>\n    dysphonia (25%), rash (25%), cough (21%), and constipation (21%).\n<\/p>\n<p>\n    In KEYNOTE-564, when KEYTRUDA was administered as a single agent for the<br \/>\n    adjuvant treatment of renal cell carcinoma, serious adverse reactions occurred<br \/>\n    in 20% of patients receiving KEYTRUDA; the serious adverse reactions (\u22651%)<br \/>\n    were acute kidney injury, adrenal insufficiency, pneumonia, colitis, and<br \/>\n    diabetic ketoacidosis (1% each). Fatal adverse reactions occurred in 0.2%<br \/>\n    including 1 case of pneumonia. Discontinuation of KEYTRUDA due to adverse<br \/>\n    reactions occurred in 21% of 488 patients; the most common (\u22651%) were<br \/>\n    increased ALT (1.6%), colitis (1%), and adrenal insufficiency (1%). The most<br \/>\n    common adverse reactions (\u226520%) were musculoskeletal pain (41%), fatigue<br \/>\n    (40%), rash (30%), diarrhea (27%), pruritus (23%), and hypothyroidism (21%).\n<\/p>\n<p>\n    Adverse reactions occurring in patients with MSI-H or dMMR endometrial<br \/>\n    carcinoma who received KEYTRUDA as a single agent were similar to those<br \/>\n    occurring in patients with melanoma or NSCLC who received KEYTRUDA as a single<br \/>\n    agent.\n<\/p>\n<p>\n    Adverse reactions occurring in patients with TMB-H cancer were similar to<br \/>\n    those occurring in patients with other solid tumors who received KEYTRUDA as a<br \/>\n    single agent.\n<\/p>\n<p>\n    Adverse reactions occurring in patients with recurrent or metastatic cSCC or<br \/>\n    locally advanced cSCC were similar to those occurring in patients with<br \/>\n    melanoma or NSCLC who received KEYTRUDA as a monotherapy.\n<\/p>\n<p>\n    In KEYNOTE-522, when KEYTRUDA was administered with neoadjuvant chemotherapy<br \/>\n    (carboplatin and paclitaxel followed by doxorubicin or epirubicin and<br \/>\n    cyclophosphamide) followed by surgery and continued adjuvant treatment with<br \/>\n    KEYTRUDA as a single agent (n=778) to patients with newly diagnosed,<br \/>\n    previously untreated, high-risk early-stage TNBC, fatal adverse reactions<br \/>\n    occurred in 0.9% of patients, including 1 each of adrenal crisis, autoimmune<br \/>\n    encephalitis, hepatitis, pneumonia, pneumonitis, pulmonary embolism, and<br \/>\n    sepsis in association with multiple organ dysfunction syndrome and myocardial<br \/>\n    infarction. Serious adverse reactions occurred in 44% of patients receiving<br \/>\n    KEYTRUDA; those \u22652% were febrile neutropenia (15%), pyrexia (3.7%), anemia<br \/>\n    (2.6%), and neutropenia (2.2%). KEYTRUDA was discontinued in 20% of patients<br \/>\n    due to adverse reactions. The most common reactions (\u22651%) resulting in<br \/>\n    permanent discontinuation were increased ALT (2.7%), increased AST (1.5%), and<br \/>\n    rash (1%). The most common adverse reactions (\u226520%) in patients receiving<br \/>\n    KEYTRUDA were fatigue (70%), nausea (67%), alopecia (61%), rash (52%),<br \/>\n    constipation (42%), diarrhea and peripheral neuropathy (41% each), stomatitis<br \/>\n    (34%), vomiting (31%), headache (30%), arthralgia (29%), pyrexia (28%), cough<br \/>\n    (26%), abdominal pain (24%), decreased appetite (23%), insomnia (21%), and<br \/>\n    myalgia (20%).\n<\/p>\n<p>\n    In KEYNOTE-355, when KEYTRUDA and chemotherapy (paclitaxel, paclitaxel<br \/>\n    protein-bound, or gemcitabine and carboplatin) were administered to patients<br \/>\n    with locally recurrent unresectable or metastatic TNBC who had not been<br \/>\n    previously treated with chemotherapy in the metastatic setting (n=596), fatal<br \/>\n    adverse reactions occurred in 2.5% of patients, including cardio-respiratory<br \/>\n    arrest (0.7%) and septic shock (0.3%). Serious adverse reactions occurred in<br \/>\n    30% of patients receiving KEYTRUDA in combination with chemotherapy; the<br \/>\n    serious reactions in \u22652% were pneumonia (2.9%), anemia (2.2%), and<br \/>\n    thrombocytopenia (2%). KEYTRUDA was discontinued in 11% of patients due to<br \/>\n    adverse reactions. The most common reactions resulting in permanent<br \/>\n    discontinuation (\u22651%) were increased ALT (2.2%), increased AST (1.5%), and<br \/>\n    pneumonitis (1.2%). The most common adverse reactions (\u226520%) in patients<br \/>\n    receiving KEYTRUDA in combination with chemotherapy were fatigue (48%), nausea<br \/>\n    (44%), alopecia (34%), diarrhea and constipation (28% each), vomiting and rash<br \/>\n    (26% each), cough (23%), decreased appetite (21%), and headache (20%).\n<\/p>\n<p>\n    <strong>Lactation<\/strong>\n<\/p>\n<p>\n    Because of the potential for serious adverse reactions in breastfed children,<br \/>\n    advise women not to breastfeed during treatment and for 4 months after the<br \/>\n    last dose.\n<\/p>\n<p>\n    <strong>Pediatric Use<\/strong>\n<\/p>\n<p>\n    In KEYNOTE-051, 173 pediatric patients (65 pediatric patients aged 6 months to<br \/>\n    younger than 12 years and 108 pediatric patients aged 12 years to 17 years)<br \/>\n    were administered KEYTRUDA 2 mg\/kg every 3 weeks. The median duration of<br \/>\n    exposure was 2.1 months (range: 1 day to 25 months).\n<\/p>\n<p>\n    Adverse reactions that occurred at a \u226510% higher rate in pediatric patients<br \/>\n    when compared to adults were pyrexia (33%), leukopenia (31%), vomiting (29%),<br \/>\n    neutropenia (28%), headache (25%), abdominal pain (23%), thrombocytopenia<br \/>\n    (22%), Grade 3 anemia (17%), decreased lymphocyte count (13%), and decreased<br \/>\n    white blood cell count (11%).\n<\/p>\n<p>\n    <strong>Geriatric Use<\/strong>\n<\/p>\n<p>\n    Of the 564 patients with locally advanced or metastatic urothelial cancer<br \/>\n    treated with KEYTRUDA in combination with enfortumab vedotin, 44% (n=247) were<br \/>\n    65-74 years and 26% (n=144) were 75 years or older. No overall differences in<br \/>\n    safety or effectiveness were observed between patients 65 years of age or<br \/>\n    older and younger patients. Patients 75 years of age or older treated with<br \/>\n    KEYTRUDA in combination with enfortumab vedotin experienced a higher incidence<br \/>\n    of fatal adverse reactions than younger patients. The incidence of fatal<br \/>\n    adverse reactions was 4% in patients younger than 75 and 7% in patients 75<br \/>\n    years or older.\n<\/p>\n<p>\n    <strong>Additional Selected KEYTRUDA Indications in the U.S.<\/strong>\n<\/p>\n<p>\n    <i>Non-Small Cell Lung Cancer<\/i>\n<\/p>\n<p>\n    KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is<br \/>\n    indicated for the first-line treatment of patients with metastatic nonsquamous<br \/>\n    non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor<br \/>\n    aberrations.\n<\/p>\n<p>\n    KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel<br \/>\n    protein-bound, is indicated for the first-line treatment of patients with<br \/>\n    metastatic squamous NSCLC.\n<\/p>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the first-line treatment of<br \/>\n    patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) \u22651%] as<br \/>\n    determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n    aberrations, and is:&nbsp;\n<\/p>\n<ul>\n<li>\n        stage III where patients are not candidates for surgical resection or<br \/>\n        definitive chemoradiation, or\n    <\/li>\n<li>metastatic.<\/li>\n<\/ul>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the treatment of patients with<br \/>\n    metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as determined by an<br \/>\n    FDA-approved test, with disease progression on or after platinum-containing<br \/>\n    chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have<br \/>\n    disease progression on FDA-approved therapy for these aberrations prior to<br \/>\n    receiving KEYTRUDA.\n<\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of patients with resectable (tumors \u22654<br \/>\n    cm or node positive) NSCLC in combination with platinum-containing<br \/>\n    chemotherapy as neoadjuvant treatment, and then continued as a single agent as<br \/>\n    adjuvant treatment after surgery.\n<\/p>\n<p>\n    KEYTRUDA, as a single agent, is indicated as adjuvant treatment following<br \/>\n    resection and platinum-based chemotherapy for adult patients with stage IB<br \/>\n    (T2a \u22654 cm), II, or IIIA NSCLC.\n<\/p>\n<p>\n    <i>Head and Neck Squamous Cell Cancer<\/i>\n<\/p>\n<p>\n    KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for<br \/>\n    the first-line treatment of patients with metastatic or with unresectable,<br \/>\n    recurrent head and neck squamous cell carcinoma (HNSCC).\n<\/p>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the first-line treatment of<br \/>\n    patients with metastatic or with unresectable, recurrent HNSCC whose tumors<br \/>\n    express PD-L1 [Combined Positive Score (CPS) \u22651] as determined by an<br \/>\n    FDA-approved test.\n<\/p>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the treatment of patients with<br \/>\n    recurrent or metastatic HNSCC with disease progression on or after<br \/>\n    platinum-containing chemotherapy.\n<\/p>\n<p>\n    <i>Classical Hodgkin Lymphoma<\/i>\n<\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of adult patients with relapsed or<br \/>\n    refractory classical Hodgkin lymphoma (cHL).\n<\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of pediatric patients with refractory<br \/>\n    cHL, or cHL that has relapsed after 2 or more lines of therapy.\n<\/p>\n<p>\n    <i>Primary Mediastinal Large B-Cell Lymphoma<\/i>\n<\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of adult and pediatric patients with<br \/>\n    refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have<br \/>\n    relapsed after 2 or more prior lines of therapy. KEYTRUDA is not recommended<br \/>\n    for treatment of patients with PMBCL who require urgent cytoreductive therapy.\n<\/p>\n<p>\n    <i>Urothelial Cancer<\/i>\n<\/p>\n<p>\n    KEYTRUDA, in combination with enfortumab vedotin, is indicated for the<br \/>\n    treatment of adult patients with locally advanced or metastatic urothelial<br \/>\n    cancer.\n<\/p>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the treatment of patients with<br \/>\n    locally advanced or metastatic urothelial carcinoma:\n<\/p>\n<ul>\n<li>who are not eligible for any platinum-containing chemotherapy, or<\/li>\n<li>\n        who have disease progression during or following platinum-containing<br \/>\n        chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with<br \/>\n        platinum-containing chemotherapy.\n    <\/li>\n<\/ul>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the treatment of patients with<br \/>\n    Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive<br \/>\n    bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary<br \/>\n    tumors who are ineligible for or have elected not to undergo cystectomy.\n<\/p>\n<p>\n    <i>Microsatellite Instability-High or Mismatch Repair Deficient Cancer<\/i>\n<\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of adult and pediatric patients with<br \/>\n    unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch<br \/>\n    repair deficient (dMMR) solid tumors, as determined by an FDA-approved test,<br \/>\n    that have progressed following prior treatment and who have no satisfactory<br \/>\n    alternative treatment options.\n<\/p>\n<p>\n    <i><br \/>\n        Microsatellite Instability-High or Mismatch Repair Deficient Colorectal<br \/>\n        Cancer<br \/>\n    <\/i>\n<\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n    metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an<br \/>\n    FDA-approved test.\n<\/p>\n<p>\n    <i>Gastric Cancer<\/i>\n<\/p>\n<p>\n    KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and<br \/>\n    platinum-containing chemotherapy, is indicated for the first-line treatment of<br \/>\n    adults with locally advanced unresectable or metastatic HER2-positive gastric<br \/>\n    or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1<br \/>\n    (CPS \u22651) as determined by an FDA-approved test.\n<\/p>\n<p>\n    This indication is approved under accelerated approval based on tumor response<br \/>\n    rate and durability of response. Continued approval of this indication may be<br \/>\n    contingent upon verification and description of clinical benefit in the<br \/>\n    confirmatory trials.\n<\/p>\n<p>\n    KEYTRUDA, in combination with fluoropyrimidine- and platinum-containing<br \/>\n    chemotherapy, is indicated for the first-line treatment of adults with locally<br \/>\n    advanced unresectable or metastatic HER2-negative gastric or gastroesophageal<br \/>\n    junction (GEJ) adenocarcinoma.\n<\/p>\n<p>\n    <i>Esophageal Cancer<\/i>\n<\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of patients with locally advanced or<br \/>\n    metastatic esophageal or gastroesophageal junction (GEJ) (tumors with<br \/>\n    epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to<br \/>\n    surgical resection or definitive chemoradiation either:\n<\/p>\n<ul>\n<li>\n        in combination with platinum- and fluoropyrimidine-based chemotherapy, or\n    <\/li>\n<li>\n        as a single agent after one or more prior lines of systemic therapy for<br \/>\n        patients with tumors of squamous cell histology that express PD-L1 (CPS \u226510)<br \/>\n        as determined by an FDA-approved test.\n    <\/li>\n<\/ul>\n<p>\n    <i>Cervical Cancer<\/i>\n<\/p>\n<p>\n    KEYTRUDA, in combination with chemoradiotherapy (CRT), is indicated for the<br \/>\n    treatment of patients with FIGO 2014 Stage III-IVA cervical cancer.\n<\/p>\n<p>\n    KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is<br \/>\n    indicated for the treatment of patients with persistent, recurrent, or<br \/>\n    metastatic cervical cancer whose tumors express PD-L1 (CPS \u22651) as determined<br \/>\n    by an FDA-approved test.\n<\/p>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the treatment of patients with<br \/>\n    recurrent or metastatic cervical cancer with disease progression on or after<br \/>\n    chemotherapy whose tumors express PD-L1 (CPS \u22651) as determined by an<br \/>\n    FDA-approved test.\n<\/p>\n<p>\n    <i>Hepatocellular Carcinoma<\/i>\n<\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of patients with hepatocellular<br \/>\n    carcinoma (HCC) secondary to hepatitis B who have received prior systemic<br \/>\n    therapy other than a PD-1\/PD-L1-containing regimen.\n<\/p>\n<p>\n    <i>Biliary Tract Cancer<\/i>\n<\/p>\n<p>\n    KEYTRUDA, in combination with gemcitabine and cisplatin, is indicated for the<br \/>\n    treatment of patients with locally advanced unresectable or metastatic biliary<br \/>\n    tract cancer (BTC).\n<\/p>\n<p>\n    <i>Merkel Cell Carcinoma<\/i>\n<\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of adult and pediatric patients with<br \/>\n    recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).\n<\/p>\n<p>\n    <i>Renal Cell Carcinoma<\/i>\n<\/p>\n<p>\n    KEYTRUDA, in combination with axitinib, is indicated for the first-line<br \/>\n    treatment of adult patients with advanced renal cell carcinoma (RCC).\n<\/p>\n<p>\n    KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at<br \/>\n    intermediate-high or high risk of recurrence following nephrectomy, or<br \/>\n    following nephrectomy and resection of metastatic lesions.\n<\/p>\n<p>\n    <i>Endometrial Carcinoma<\/i>\n<\/p>\n<p>\n    KEYTRUDA, as a single agent, is indicated for the treatment of patients with<br \/>\n    advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an<br \/>\n    FDA-approved test, who have disease progression following prior systemic<br \/>\n    therapy in any setting and are not candidates for curative surgery or<br \/>\n    radiation.\n<\/p>\n<p>\n    <i>Tumor Mutational Burden-High Cancer<\/i>\n<\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of adult and pediatric patients with<br \/>\n    unresectable or metastatic tumor mutational burden-high (TMB-H) [\u226510<br \/>\n    mutations\/megabase (mut\/Mb)] solid tumors, as determined by an FDA-approved<br \/>\n    test, that have progressed following prior treatment and who have no<br \/>\n    satisfactory alternative treatment options. This indication is approved under<br \/>\n    accelerated approval based on tumor response rate and durability of response.<br \/>\n    Continued approval for this indication may be contingent upon verification and<br \/>\n    description of clinical benefit in the confirmatory trials. The safety and<br \/>\n    effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous<br \/>\n    system cancers have not been established.\n<\/p>\n<p>\n    <i>Cutaneous Squamous Cell Carcinoma<\/i>\n<\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n    metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC<br \/>\n    that is not curable by surgery or radiation.\n<\/p>\n<p>\n    <i>Triple-Negative Breast Cancer<\/i>\n<\/p>\n<p>\n    KEYTRUDA is indicated for the treatment of patients with high-risk early-stage<br \/>\n    triple-negative breast cancer (TNBC) in combination with chemotherapy as<br \/>\n    neoadjuvant treatment, and then continued as a single agent as adjuvant<br \/>\n    treatment after surgery.\n<\/p>\n<p>\n    KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of<br \/>\n    patients with locally recurrent unresectable or metastatic TNBC whose tumors<br \/>\n    express PD-L1 (CPS \u226510) as determined by an FDA-approved test.\n<\/p>\n<p>\n    <strong>Merck\u2019s focus on cancer<\/strong>\n<\/p>\n<p>\n    Every day, we follow the science as we work to discover innovations that can<br \/>\n    help patients, no matter what stage of cancer they have. As a leading oncology<br \/>\n    company, we are pursuing research where scientific opportunity and medical<br \/>\n    need converge, underpinned by our diverse pipeline of more than 25 novel<br \/>\n    mechanisms. With one of the largest clinical development programs across more<br \/>\n    than 30 tumor types, we strive to advance breakthrough science that will shape<br \/>\n    the future of oncology. By addressing barriers to clinical trial<br \/>\n    participation, screening and treatment, we work with urgency to reduce<br \/>\n    disparities and help ensure patients have access to high-quality cancer care.<br \/>\n    Our unwavering commitment is what will bring us closer to our goal of bringing<br \/>\n    life to more patients with cancer. For more information, visit<br \/>\n    <a href=\"https:\/\/www.merck.com\/research\/oncology\/\">https:\/\/www.merck.com\/research\/oncology\/<\/a>.\n<\/p>\n<p>\n    <strong>About Merck\u2019s research in melanoma<\/strong>\n<\/p>\n<p>\n    Merck is committed to delivering meaningful advances for patients with<br \/>\n    melanoma and to continuing research in skin cancers through a broad clinical<br \/>\n    development program across investigational and approved medicines. KEYTRUDA<br \/>\n    has been established as an important treatment option for the adjuvant<br \/>\n    treatment of patients with resected Stage IIB, IIC, or III melanoma based on<br \/>\n    results of KEYNOTE-054 and KEYNOTE-716. KEYTRUDA is also approved worldwide<br \/>\n    for the treatment of patients with unresectable or metastatic melanoma.\n<\/p>\n<p>\n    <strong>About Merck<\/strong>\n<\/p>\n<p>\n    At Merck, known as MSD outside of the United States and Canada, we are unified<br \/>\n    around our purpose: We use the power of leading-edge science to save and<br \/>\n    improve lives around the world. For more than 130 years, we have brought hope<br \/>\n    to humanity through the development of important medicines and vaccines. We<br \/>\n    aspire to be the premier research-intensive biopharmaceutical company in the<br \/>\n    world \u2013 and today, we are at the forefront of research to deliver innovative<br \/>\n    health solutions that advance the prevention and treatment of diseases in<br \/>\n    people and animals. We foster a diverse and inclusive global workforce and<br \/>\n    operate responsibly every day to enable a safe, sustainable and healthy future<br \/>\n    for all people and communities.\u202fFor more information, visit<br \/>\n    <a href=\"https:\/\/www.merck.com\/\">www.merck.com<\/a>\u202fand connect with us on\u202f<br \/>\n    <a href=\"https:\/\/twitter.com\/Merck\">X (formerly Twitter)<\/a>,<br \/>\n    <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\">Facebook<\/a>,<br \/>\n    <a href=\"https:\/\/www.instagram.com\/merck\/\">Instagram<\/a>,<br \/>\n    <a href=\"https:\/\/www.youtube.com\/Merck\">YouTube<\/a> and<br \/>\n    <a href=\"https:\/\/www.linkedin.com\/company\/merck\/\">LinkedIn<\/a>.\n<\/p>\n<p>\n    <strong>About Moderna<\/strong>\n<\/p>\n<p>\n    Moderna is a leader in the creation of the field of mRNA medicine. Through the<br \/>\n    advancement of mRNA technology, Moderna is reimagining how medicines are made<br \/>\n    and transforming how we treat and prevent disease for everyone. By working at<br \/>\n    the intersection of science, technology and health for more than a decade, the<br \/>\n    company has developed medicines at unprecedented speed and efficiency,<br \/>\n    including one of the earliest and most effective COVID-19 vaccines.&nbsp;\n<\/p>\n<p>\n    Moderna\u2019s mRNA platform has enabled the development of therapeutics and<br \/>\n    vaccines for infectious diseases, immuno-oncology, rare diseases and<br \/>\n    autoimmune diseases. With a unique culture and a global team driven by the<br \/>\n    Moderna values and mindsets to responsibly change the future of human health,<br \/>\n    Moderna strives to deliver the greatest possible impact to people through mRNA<br \/>\n    medicines. For more information about Moderna, please visit <a href=\"http:\/\/www.modernatx.com\/\">modernatx.com<\/a><br \/>\n    and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and<br \/>\n    LinkedIn.&nbsp;\n<\/p>\n<p>\n    <strong>Moderna\u2019s focus on cancer<\/strong>\n<\/p>\n<p>\n    At Moderna, we are delivering on the promise of mRNA science to create a<br \/>\n    new&nbsp;generation of transformative medicines for patients. We are<br \/>\n    relentlessly&nbsp;working to grow our cancer therapeutic modality by discovering<br \/>\n    mRNA medicines&nbsp;that harness the body\u2019s immune system to identify and kill<br \/>\n    cancer cells&nbsp;in the same way the immune system identifies and targets<br \/>\n    infections. One&nbsp;example of a promising oncology candidate is the creation of<br \/>\n    individualized,&nbsp;mRNA-based cancer therapies. We also continue to strengthen<br \/>\n    our portfolio&nbsp;through strategic collaborations that increase our potential to<br \/>\n    improve&nbsp;treatment options for patients with cancer.\n<\/p>\n<p>\n    <strong><br \/>\n        Forward-Looking Statement of Merck &amp; Co., Inc., Rahway, N.J., USA<br \/>\n    <\/strong>\n<\/p>\n<p>\n    This news release of Merck &amp; Co., Inc., Rahway, N.J., USA (the \u201ccompany\u201d)<br \/>\n    includes \u201cforward-looking statements\u201d within the meaning of the safe harbor<br \/>\n    provisions of the U.S. Private Securities Litigation Reform Act of 1995. These<br \/>\n    statements are based upon the current beliefs and expectations of the<br \/>\n    company\u2019s management and are subject to significant risks and uncertainties.<br \/>\n    There can be no guarantees with respect to pipeline candidates that the<br \/>\n    candidates will receive the necessary regulatory approvals or that they will<br \/>\n    prove to be commercially successful. If underlying assumptions prove<br \/>\n    inaccurate or risks or uncertainties materialize, actual results may differ<br \/>\n    materially from those set forth in the forward-looking statements.\n<\/p>\n<p>\n    Risks and uncertainties include but are not limited to, general industry<br \/>\n    conditions and competition; general economic factors, including interest rate<br \/>\n    and currency exchange rate fluctuations; the impact of pharmaceutical industry<br \/>\n    regulation and health care legislation in the United States and<br \/>\n    internationally; global trends toward health care cost containment;<br \/>\n    technological advances, new products and patents attained by competitors;<br \/>\n    challenges inherent in new product development, including obtaining regulatory<br \/>\n    approval; the company\u2019s ability to accurately predict future market<br \/>\n    conditions; manufacturing difficulties or delays; financial instability of<br \/>\n    international economies and sovereign risk; dependence on the effectiveness of<br \/>\n    the company\u2019s patents and other protections for innovative products; and the<br \/>\n    exposure to litigation, including patent litigation, and\/or regulatory<br \/>\n    actions.\n<\/p>\n<p>\n    The company undertakes no obligation to publicly update any forward-looking<br \/>\n    statement, whether as a result of new information, future events or otherwise.<br \/>\n    Additional factors that could cause results to differ materially from those<br \/>\n    described in the forward-looking statements can be found in the company\u2019s<br \/>\n    Annual Report on Form 10-K for the year ended December 31, 2023 and the<br \/>\n    company\u2019s other filings with the Securities and Exchange Commission (SEC)<br \/>\n    available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\">www.sec.gov<\/a>).\n<\/p>\n<p>\n    <strong>Moderna Forward-Looking Statements<\/strong>\n<\/p>\n<p>\n    This press release contains forward-looking statements within the meaning of<br \/>\n    the Private Securities Litigation Reform Act of 1995, as amended, including<br \/>\n    statements regarding: the ability for mRNA-4157\/V940 and KEYTRUDA to<br \/>\n    demonstrate a clinically meaningful improvement in recurrence-free survival<br \/>\n    and distant metastasis-free survival compared with KEYTRUDA alone, the<br \/>\n    tolerability and safety profile for mRNA-4157\/V940; the ability of an<br \/>\n    individualized neoantigen therapy to trigger a tailored antitumor response<br \/>\n    specific to a patient&#8217;s tumor mutation signature; and the conduct of<br \/>\n    additional trials and plans for studying individualized neoantigen therapy in<br \/>\n    additional types of cancer. The forward-looking statements in this press<br \/>\n    release are neither promises nor guarantees, and you should not place undue<br \/>\n    reliance on these forward-looking statements because they involve known and<br \/>\n    unknown risks, uncertainties, and other factors, many of which are beyond<br \/>\n    Moderna&#8217;s control and which could cause actual results to differ materially<br \/>\n    from those expressed or implied by these forward-looking statements. These<br \/>\n    risks, uncertainties, and other factors include, among others, those risks and<br \/>\n    uncertainties described under the heading &#8220;Risk Factors&#8221; in Moderna&#8217;s Annual<br \/>\n    Report on Form 10-K for the fiscal year ended December 31, 2023, filed with<br \/>\n    the U.S. Securities and Exchange Commission (SEC), and in subsequent filings<br \/>\n    made by Moderna with the SEC, which are available on the SEC&#8217;s website at<br \/>\n    <a href=\"https:\/\/www.sec.gov\/\">www.sec.gov<\/a>. Except as required by law,<br \/>\n    Moderna disclaims any intention or responsibility for updating or revising any<br \/>\n    forward-looking statements contained in this press release in the event of new<br \/>\n    information, future developments or otherwise. These forward-looking<br \/>\n    statements are based on Moderna&#8217;s current expectations and speak only as of<br \/>\n    the date of this press release.\n<\/p>\n<p>\n    <strong><br \/>\n        Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/strong><a href=\"https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf\">http:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/a><strong><br \/>\n        and Medication Guide for KEYTRUDA at <\/strong><a href=\"https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf\">https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/a>\n<\/p>\n<p>Merck Media Contacts:<\/p>\n<p>\n    Sienna Choi<br \/>\n    (908) 873-4311<\/p>\n<p>    Julie Cunningham<br \/>\n    (617) 519-6264\n<\/p>\n<p>Merck Investor Contacts:<\/p>\n<p>\n    Peter Dannenbaum<br \/>\n    (732) 594-1579<\/p>\n<p>    Damini Chokshi<br \/>\n    (732) 594-1577\n<\/p>\n<p>Moderna Media Contacts:<\/p>\n<p>\n    Luke Mircea-Willats Senior Director, International Communications <br \/>\n    <a href=\"mailto:Luke.mirceawillats@modernatx.com\"><br \/>\n        Luke.mirceawillats@modernatx.com<br \/>\n    <\/a>\n<\/p>\n<p>Moderna Investor Contacts:<\/p>\n<p>\n    Lavina Talukdar Senior Vice President &amp; Head of Investor Relations <br \/>\n    <a href=\"mailto:lavina.talukdar@modernatx.com\"><br \/>\n        lavina.talukdar@modernatx.com<br \/>\n    <\/a><br \/>\n    <br \/>\n    617-209-5834\n<\/p>\n<style><\/style>\n","protected":false},"excerpt":{"rendered":"<p>At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patients The 2.5-year recurrence-free survival rate of mRNA-4157 (V940) in combination with KEYTRUDA was 74.8% as compared to 55.6% for KEYTRUDA alone, with the benefit observed across exploratory subgroups The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer, in addition to Phase 2 studies in patients with renal cell carcinoma and urothelial carcinoma and a Phase 2\/3 study for cutaneous squamous cell carcinoma CAMBRIDGE, Mass. and RAHWAY, N.J., June 3, 2024 \u2013 Moderna, Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from a planned analysis from the Phase 2b randomized<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[289],"class_list":["post-3650299","news_item","type-news_item","status-publish","hentry","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Moderna &amp; Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival &amp; Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III\/IV Melanoma Following Complete Resection - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moderna &amp; Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival &amp; Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III\/IV Melanoma Following Complete Resection - Merck.com\" \/>\n<meta property=\"og:description\" content=\"At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patients The 2.5-year recurrence-free survival rate of mRNA-4157 (V940) in combination with KEYTRUDA was 74.8% as compared to 55.6% for KEYTRUDA alone, with the benefit observed across exploratory subgroups The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer, in addition to Phase 2 studies in patients with renal cell carcinoma and urothelial carcinoma and a Phase 2\/3 study for cutaneous squamous cell carcinoma CAMBRIDGE, Mass. and RAHWAY, N.J., June 3, 2024 \u2013 Moderna, Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from a planned analysis from the Phase 2b randomized\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-31T17:58:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"47 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\\\/\",\"name\":\"Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III\\\/IV Melanoma Following Complete Resection - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2024-06-03T12:00:00+00:00\",\"dateModified\":\"2025-12-31T17:58:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moderna &#038; Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival &#038; Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III\\\/IV Melanoma Following Complete Resection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III\/IV Melanoma Following Complete Resection - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\/","og_locale":"en_US","og_type":"article","og_title":"Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III\/IV Melanoma Following Complete Resection - Merck.com","og_description":"At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patients The 2.5-year recurrence-free survival rate of mRNA-4157 (V940) in combination with KEYTRUDA was 74.8% as compared to 55.6% for KEYTRUDA alone, with the benefit observed across exploratory subgroups The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer, in addition to Phase 2 studies in patients with renal cell carcinoma and urothelial carcinoma and a Phase 2\/3 study for cutaneous squamous cell carcinoma CAMBRIDGE, Mass. and RAHWAY, N.J., June 3, 2024 \u2013 Moderna, Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from a planned analysis from the Phase 2b randomized","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\/","og_site_name":"Merck.com","article_modified_time":"2025-12-31T17:58:07+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"47 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\/","name":"Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III\/IV Melanoma Following Complete Resection - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2024-06-03T12:00:00+00:00","dateModified":"2025-12-31T17:58:07+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Moderna &#038; Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA\u00ae (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival &#038; Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III\/IV Melanoma Following Complete Resection"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"ca3e036a-6c7f-49be-9eb6-eacbb0e58f7d","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Moderna--Merck-Announce-Three-Year-Follow-Up-Data-for-mRNA-4157-V940-in-Combination-With-KEYTRUDA-2024.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/3650299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":3,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/3650299\/revisions"}],"predecessor-version":[{"id":3678717,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/3650299\/revisions\/3678717"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=3650299"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=3650299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}